Harvard Bioscience Inc. (HBIO) Short-Term Debt to Capital

The visualized price action for Harvard Bioscience (HBIO) demonstrates the dynamics of an asset whose resilience is based on balanced equipment supplies for global biolabs and pharma behemoths. Harvard Bioscience relies on its own capacities in Europe and the US, producing precision equipment for universities. Patents and strict FDA oversight ensure a high barrier to entry, while the metric stands at 0.00.

This indicator measures the proportion of short-term liabilities relative to equity, allowing for an assessment of liquidity risk and the company's degree of financial leverage. By analyzing the short-term debt-to-equity ratio on GURU.Markets, an investor will see how the modernization of CNC lines and high shop capacity utilization at Harvard Bioscience (HBIO) are financed through borrowed funds, which determines the balance between production expansion and portfolio stability.